These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 34140489)

  • 41. CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice.
    Xu L; Park KH; Zhao L; Xu J; El Refaey M; Gao Y; Zhu H; Ma J; Han R
    Mol Ther; 2016 Mar; 24(3):564-9. PubMed ID: 26449883
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System.
    Zhang Y; Bassel-Duby R; Olson EN
    Methods Mol Biol; 2023; 2587():411-425. PubMed ID: 36401041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
    Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.
    Young CS; Hicks MR; Ermolova NV; Nakano H; Jan M; Younesi S; Karumbayaram S; Kumagai-Cresse C; Wang D; Zack JA; Kohn DB; Nakano A; Nelson SF; Miceli MC; Spencer MJ; Pyle AD
    Cell Stem Cell; 2016 Apr; 18(4):533-40. PubMed ID: 26877224
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Live-imaging of revertant and therapeutically restored dystrophin in the Dmd
    Petkova MV; Stantzou A; Morin A; Petrova O; Morales-Gonzalez S; Seifert F; Bellec-Dyevre J; Manoliu T; Goyenvalle A; Garcia L; Richard I; Laplace-Builhé C; Schuelke M; Amthor H
    Neuropathol Appl Neurobiol; 2020 Oct; 46(6):602-614. PubMed ID: 32573804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. AAV-mediated overexpression of human α7 integrin leads to histological and functional improvement in dystrophic mice.
    Heller KN; Montgomery CL; Janssen PM; Clark KR; Mendell JR; Rodino-Klapac LR
    Mol Ther; 2013 Mar; 21(3):520-5. PubMed ID: 23319059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular Dystrophy.
    Happi Mbakam C; Rousseau J; Tremblay G; Yameogo P; Tremblay JP
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice.
    Zhang Y; Long C; Li H; McAnally JR; Baskin KK; Shelton JM; Bassel-Duby R; Olson EN
    Sci Adv; 2017 Apr; 3(4):e1602814. PubMed ID: 28439558
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models.
    Hakim CH; Kumar SRP; Pérez-López DO; Wasala NB; Zhang D; Yue Y; Teixeira J; Pan X; Zhang K; Million ED; Nelson CE; Metzger S; Han J; Louderman JA; Schmidt F; Feng F; Grimm D; Smith BF; Yao G; Yang NN; Gersbach CA; Chen SJ; Herzog RW; Duan D
    Nat Commun; 2021 Nov; 12(1):6769. PubMed ID: 34819506
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
    Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
    Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
    Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
    Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.
    Zhang Y; Yue Y; Li L; Hakim CH; Zhang K; Thomas GD; Duan D
    Hum Mol Genet; 2013 Sep; 22(18):3720-9. PubMed ID: 23681067
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo gene editing in dystrophic mouse muscle and muscle stem cells.
    Tabebordbar M; Zhu K; Cheng JKW; Chew WL; Widrick JJ; Yan WX; Maesner C; Wu EY; Xiao R; Ran FA; Cong L; Zhang F; Vandenberghe LH; Church GM; Wagers AJ
    Science; 2016 Jan; 351(6271):407-411. PubMed ID: 26721686
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel adeno-associated viral vector delivering the utrophin gene regulator jazz counteracts dystrophic pathology in mdx mice.
    Strimpakos G; Corbi N; Pisani C; Di Certo MG; Onori A; Luvisetto S; Severini C; Gabanella F; Monaco L; Mattei E; Passananti C
    J Cell Physiol; 2014 Sep; 229(9):1283-91. PubMed ID: 24469912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lentiviral Micro-dystrophin Gene Treatment into Late-stage mdx Mice for Duchenne Muscular Dystrophy Disease.
    Eren SA; Tastan C; Karadeniz KB; Turan RD; Cakirsoy D; Kancagi DD; Yilmaz SU; Oztatlici M; Oztatlici H; Ozer S; Tumentemur G; Baykal AT; Ovali E
    Curr Gene Ther; 2023; 23(4):304-315. PubMed ID: 37032509
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
    Yin H; Moulton HM; Betts C; Seow Y; Boutilier J; Iverson PL; Wood MJ
    Hum Mol Genet; 2009 Nov; 18(22):4405-14. PubMed ID: 19692354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
    Aslesh T; Erkut E; Yokota T
    Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
    [No Abstract]   [Full Text] [Related]  

  • 59. CRISPR-Editing Therapy for Duchenne Muscular Dystrophy.
    Chemello F; Olson EN; Bassel-Duby R
    Hum Gene Ther; 2023 May; 34(9-10):379-387. PubMed ID: 37060194
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dystrophin restoration therapy improves both the reduced excitability and the force drop induced by lengthening contractions in dystrophic mdx skeletal muscle.
    Roy P; Rau F; Ochala J; Messéant J; Fraysse B; Lainé J; Agbulut O; Butler-Browne G; Furling D; Ferry A
    Skelet Muscle; 2016; 6():23. PubMed ID: 27441081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.